2022 Q3 Form 10-Q Financial Statement
#000095017022015543 Filed on August 08, 2022
Income Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|
Balance Sheet
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $53.71M | $61.99M | $70.08M |
YoY Change | -37.05% | 20253.6% | 11662.61% |
Cash & Equivalents | $53.70M | $62.00M | $70.10M |
Short-Term Investments | |||
Other Short-Term Assets | $1.941M | $1.221M | $1.623M |
YoY Change | -26.34% | 24232.83% | |
Inventory | |||
Prepaid Expenses | $1.221M | $1.623M | |
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $55.65M | $63.21M | $71.71M |
YoY Change | -36.73% | 20654.48% | 11801.77% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.441M | $913.0K | $362.0K |
YoY Change | 7105.0% | ||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $163.0K | $56.00K | $42.00K |
YoY Change | |||
Total Long-Term Assets | $2.088M | $1.508M | $404.0K |
YoY Change | 10340.0% | -98.25% | -99.53% |
TOTAL ASSETS | |||
Total Short-Term Assets | $55.65M | $63.21M | $71.71M |
Total Long-Term Assets | $2.088M | $1.508M | $404.0K |
Total Assets | $57.74M | $64.72M | $72.11M |
YoY Change | -34.37% | -25.23% | -16.97% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $3.228M | $1.546M | $1.781M |
YoY Change | 114.91% | -19.39% | 57.65% |
Accrued Expenses | $3.945M | $2.341M | $1.616M |
YoY Change | 80.63% | ||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | -100.0% | |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $8.433M | $4.125M | $3.397M |
YoY Change | 128.78% | -33.07% | -43.1% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $2.918M | $7.975M |
YoY Change | -100.0% | ||
Other Long-Term Liabilities | $6.601M | $327.0K | $7.975M |
YoY Change | -78.62% | ||
Total Long-Term Liabilities | $6.601M | $3.245M | $7.975M |
YoY Change | -78.62% | ||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $8.433M | $4.125M | $3.397M |
Total Long-Term Liabilities | $6.601M | $3.245M | $7.975M |
Total Liabilities | $15.03M | $7.370M | $11.37M |
YoY Change | -56.5% | 19.59% | 90.49% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$31.70M | -$16.40M | -$12.40M |
YoY Change | 71.35% | ||
Common Stock | $74.36M | $73.78M | $73.14M |
YoY Change | 3.46% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $42.71M | $57.35M | $60.74M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $57.74M | $64.72M | $72.11M |
YoY Change | -34.37% | -25.23% | -16.97% |
Cashflow Statement
Concept | 2022 Q3 | 2022 Q2 | 2022 Q1 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001799850 | ||
CY2022Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2022Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-06-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-39271 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Renovacor, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
83-3169838 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
201 Broadway | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 310 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Cambridge | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02139 | ||
dei |
City Area Code
CityAreaCode
|
610 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
424-2650 | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
78790000 | |
CY2022Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
17267690 | |
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
61993000 | |
CY2022Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1221000 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1763000 | |
CY2022Q2 | us-gaap |
Assets Current
AssetsCurrent
|
63214000 | |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
80553000 | |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
913000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
379000 | |
CY2022Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
539000 | |
CY2022Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
56000 | |
CY2021Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
67000 | |
CY2022Q2 | us-gaap |
Assets
Assets
|
64722000 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
80999000 | |
CY2022Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1546000 | |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1536000 | |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2341000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2498000 | |
CY2022Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
238000 | |
CY2022Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4125000 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4034000 | |
CY2022Q2 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
980000 | |
CY2021Q4 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
11165000 | |
CY2022Q2 | rcor |
Share Earnout Liability
ShareEarnoutLiability
|
1938000 | |
CY2021Q4 | rcor |
Share Earnout Liability
ShareEarnoutLiability
|
12256000 | |
CY2022Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
327000 | |
CY2022Q2 | us-gaap |
Liabilities
Liabilities
|
7370000 | |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
27455000 | |
CY2022Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2022Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
16767690 | |
CY2022Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
16767690 | |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
16756042 | |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
16756042 | |
CY2022Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
CY2022Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
73778000 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
72540000 | |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-16428000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5763000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
912000 | ||
CY2022Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2838000 | |
CY2021Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
385000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-18998000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
57352000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
53544000 | |
CY2022Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
64722000 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
80999000 | |
CY2022Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6289000 | |
CY2021Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3333000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12219000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4488000 | ||
CY2022Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9127000 | |
CY2021Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3718000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17982000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5400000 | ||
CY2022Q2 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
45000 | |
us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
49000 | ||
CY2022Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-2905000 | |
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-10185000 | ||
CY2022Q2 | rcor |
Loss On Change In Fair Value Of Share Earnout Liability
LossOnChangeInFairValueOfShareEarnoutLiability
|
-2152000 | |
rcor |
Loss On Change In Fair Value Of Share Earnout Liability
LossOnChangeInFairValueOfShareEarnoutLiability
|
-10318000 | ||
CY2022Q2 | us-gaap |
Other Expenses
OtherExpenses
|
1000 | |
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4024000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3718000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
2570000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-5400000 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.23 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.59 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.14 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.86 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.23 | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.59 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.14 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.86 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17478008 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17471341 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
17478008 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6274566 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
17550126 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6274566 | ||
us-gaap |
Profit Loss
ProfitLoss
|
2570000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-5400000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1233000 | ||
CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
449000 | |
rcor |
Deferred Merger Costs In Accounts Payable
DeferredMergerCostsInAccountsPayable
|
1439000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
192000 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-10185000 | ||
rcor |
Loss On Change In Fair Value Of Share Earnout Liability
LossOnChangeInFairValueOfShareEarnoutLiability
|
-10318000 | ||
us-gaap |
Depreciation
Depreciation
|
36000 | ||
us-gaap |
Depreciation
Depreciation
|
1000 | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-542000 | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
438000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-95000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1157000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
150000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
438000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-37000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16030000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4050000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
719000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-719000 | ||
us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
53000 | ||
us-gaap |
Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
|
885000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-48000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-885000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-16797000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-4935000 | ||
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
78790000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
5384000 | |
CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
61993000 | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
211000 | ||
rcor |
Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
|
59000 | ||
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
575000 | ||
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
53544000 | |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
601000 | |
CY2022Q1 | us-gaap |
Profit Loss
ProfitLoss
|
6594000 | |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
60739000 | |
CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5000 | |
CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
632000 | |
CY2022Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-4024000 | |
CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
57352000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5298000 | |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7000 | |
CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-1681000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3624000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
185000 | |
CY2021Q2 | us-gaap |
Profit Loss
ProfitLoss
|
-3719000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
90000 | |
CY2022Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-16400000 | |
CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
347000 | |
CY2022Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
144000 | |
CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
62000000.0 | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expense, and related disclosures. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Estimates relied upon in preparing these financial statements relate to, but are not limited to, the fair value of financial instruments, stock-based compensation assumptions and accrued expenses (including accrued and prepaid clinical costs). Actual results may differ from these estimates under different assumptions or conditions.</span></p> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash primarily held at one financial institution, which, at times, may exceed federally insured limits, and cash equivalents consisting of investments in money market funds managed by a variety of financial institutions. The Company's credit risk is managed by investing in only highly rated money market instruments. As a result, no significant additional credit risk is believed by management to be inherent in the Company’s assets and the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk on such accounts</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p> | ||
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | ||
us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | ||
CY2022Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2022Q2 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
rcor |
Earnout Shares
EarnoutShares
|
2422816 | ||
rcor |
Settlement Of Convertible Note At Closing
SettlementOfConvertibleNoteAtClosing
|
2500000 | ||
rcor |
Effect Of Merger Net Of Redemptions And Transaction Costs Included In Cash Flow
EffectOfMergerNetOfRedemptionsAndTransactionCostsIncludedInCashFlow
|
86541000 | ||
CY2022Q2 | rcor |
Shares Of Common Stock Immediately After Merger
SharesOfCommonStockImmediatelyAfterMerger
|
17256042 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17471341 | ||
CY2022Q2 | rcor |
Laboratory Equipment Gross
LaboratoryEquipmentGross
|
897000 | |
CY2021Q4 | rcor |
Laboratory Equipment Gross
LaboratoryEquipmentGross
|
380000 | |
CY2022Q2 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
53000 | |
CY2022Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
950000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
380000 | |
CY2022Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
37000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1000 | |
CY2022Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
913000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
379000 | |
CY2022Q2 | rcor |
Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
|
530000 | |
CY2021Q4 | rcor |
Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
|
209000 | |
CY2022Q2 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
401000 | |
CY2021Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
1369000 | |
CY2022Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
290000 | |
CY2021Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
185000 | |
CY2022Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1221000 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1763000 | |
CY2022Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1339000 | |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1282000 | |
CY2022Q2 | rcor |
External Research And Development Expenses
ExternalResearchAndDevelopmentExpenses
|
639000 | |
CY2021Q4 | rcor |
External Research And Development Expenses
ExternalResearchAndDevelopmentExpenses
|
409000 | |
CY2022Q2 | rcor |
Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
|
53000 | |
CY2021Q4 | rcor |
Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
|
360000 | |
CY2022Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
166000 | |
us-gaap |
Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
|
options to extend | ||
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
146000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
254000 | |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
100000 | |
CY2022Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2341000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2498000 | |
us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | ||
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
76000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
16000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
17000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
124000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
633000 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
68000 | |
CY2022Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
565000 | |
CY2022Q2 | rcor |
Future Lease Payments Not Recorded On Balance Sheets
FutureLeasePaymentsNotRecordedOnBalanceSheets
|
5000000.0 | |
CY2022Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P10Y3M18D | |
us-gaap |
Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
|
true | ||
us-gaap |
Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
|
right to terminate | ||
CY2022Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y2M26D | |
CY2022Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0297 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
100000 | ||
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
0 | ||
CY2022Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2022Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
6000000 | |
CY2021Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1987636 | |
CY2021Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1987636 | |
CY2022Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
CY2022Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
us-gaap |
Preferred Stock Voting Rights
PreferredStockVotingRights
|
no | ||
CY2022Q2 | rcor |
Warrants Outstanding
WarrantsOutstanding
|
12837868 | |
CY2021Q4 | rcor |
Warrants Outstanding
WarrantsOutstanding
|
12837868 | |
CY2022Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
13638855 | |
CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
632000 | |
CY2021Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
185000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1233000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
192000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.99 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.36 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
600000 | ||
CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4024000 | |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3718000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
2570000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-5400000 | ||
us-gaap |
Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
|
72000 | ||
CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4024000 | |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3718000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
2498000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5400000 | ||
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4024000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3718000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
2498000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5400000 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17478008 | |
CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-4024000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | ||
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-3718000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
2498000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-5400000 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17478008 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
17471341 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6274566 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.23 | |
CY2021Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.59 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.14 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.86 | ||
CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4024000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3718000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
2570000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-5400000 | ||
us-gaap |
Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
|
72000 | ||
rcor |
Incremental Common Shares Attributable To Underlying In The Money Options Outstanding
IncrementalCommonSharesAttributableToUnderlyingInTheMoneyOptionsOutstanding
|
39153 | ||
rcor |
Incremental Common Shares Attributable To Underlying Time Based Restricted Stock Units
IncrementalCommonSharesAttributableToUnderlyingTimeBasedRestrictedStockUnits
|
39632 | ||
CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
17478008 | |
CY2021Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6274566 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
17550126 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6274566 | ||
CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.23 | |
CY2021Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.59 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.14 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.86 | ||
CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16920533 | |
CY2021Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
194926 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
16606561 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
194926 |